Thursday, February 20, 2020
News on Pathogens and Preparedness

2020 NIAID Omnibus Broad Agency Announcement

Consider submitting a proposal through the 2020 NIAID Omnibus Broad Agency Announcement (BAA) if you can carry out research supporting program objectives of NIAID’s Division of Allergy, Immunology, and Transplantation (DAIT) and Division of Microbiology and Infectious Diseases (DMID).

The BAA contains five distinct research areas—one for DAIT and four for DMID—which we briefly describe below. You may respond to one, any combination of, or all of the areas. For complete details, read the full solicitation and amendments.

Direct inquiries about a particular research area to the contracting officer listed in the following:

Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs)

  • Division and Contact: DAIT, Liem Nguyen
  • Description: Supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries resulting from exposure to ionizing radiation from a radiological or nuclear incident, thereby leading to a reduction in radiation-associated morbidities and mortalities.
  • Number of Awards/Total Costs: One or two cost-reimbursement, completion type contracts for an average annual total cost (direct and indirect costs combined) of up to $2 million each for a non-severable base and option periods.
  • Performance Period: Not to exceed three years (Base plus Options)
  • Due Date: April 9, 2020, by 3 p.m. Eastern Time
  • Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website

Research Area 002: Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated With Enterovirus D68

  • Division and Contacts: DMID, Swee L. Teo and Brian Madgey
  • Description: Supports the development of inactivated Enterovirus D68 vaccines, preferably using adjuvants that minimize regulatory concerns and expedite vaccine development into a Phase I clinical trial.
  • Number of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $3 million for the non-severable base work across all contracts (direct and indirect costs combined).
  • Performance Period: Not to exceed five years (Base plus Options)
  • Due Date: February 28, 2020, by 3 p.m. Eastern Time
  • Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website

Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

  • Division and Contacts: DMID,Swee L. Teo and Brian Madgey
  • Description: Supports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp.Pseudomonas aeruginosaFrancisella tularensisYersinia pestis, and E. coli, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (e.g., Eastern Equine Encephalitis) and bunyaviruses (e.g., Rift Valley Fever Virus).
  • Number of Awards/Total Costs: NIAID estimates that three or more awards may be issued across Research Areas 003 and 004 for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined).
  • Performance Period: Not to exceed five years (Base plus Options)
  • Due Date: April 9, 2020, by 3 p.m. Eastern Time
  • Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website

Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections, and Emerging Infectious Diseases

  • Division and Contacts: DMID,Swee L. Teo and Brian Madgey
  • Description: Supports development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 , including optimization, preclinical (investigational new drug-enabling), and clinical trials that include Phase I and Phase II studies.
  • Number of Awards/Total Costs: NIAID estimates that three or more awards may be issued across Research Areas 003 and 004 for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined).
  • Performance Period: Not to exceed five years (Base plus Options)
  • Due Date: April 9, 2020, by 3 p.m. Eastern Time
  • Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website

Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases

  • Division and Contacts: DMID, Swee L. Teo and Brian Madgey
  • Description: Supports advancing the development of novel, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness.
  • Number of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined).
  • Total Performance Period: Not to exceed five years (Base plus Options)
  • Due Date: April 9, 2020, by 3 p.m. Eastern Time
  • Proposal Submission: Online through the NIAID electronic Contract Proposal Submission (eCPS) website

Related Posts